Page 8 - Repligen Co News Today

Repligen Co. (NASDAQ:RGEN – Get Rating) shares traded up 4.3% during mid-day trading on Wednesday . The stock traded as high as $178.26 and last traded at $177.66. 322,077 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 547,335 shares. The stock had previously closed at $170.39. Analysts […]

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have received a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the […]

Repligen Co. (NASDAQ:RGEN – Get Rating) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average […]

Comerica Bank boosted its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 11.7% in the fourth quarter, HoldingsChannel reports. The firm owned 117,682 shares of the biotechnology company’s stock after buying an additional 12,309 shares during the period. Comerica Bank’s holdings in Repligen were worth $21,850,000 as of its most recent SEC filing. A […]

Inspire Investing LLC lifted its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 19.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,163 shares of the biotechnology company’s stock after purchasing an additional 1,320 shares during […]

Repligen Co. (NASDAQ:RGEN – Get Rating)’s stock price shot up 4.5% during mid-day trading on Monday . The company traded as high as $167.87 and last traded at $167.40. 133,416 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 571,400 shares. The stock had previously closed at $160.25. […]

Bank of New York Mellon Corp cut its stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 2.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 983,641 shares of the biotechnology company’s stock after selling 23,204 shares during the quarter. Bank of New York Mellon Corp’s holdings in Repligen were worth $184,049,000 […]

Repligen Co. (NASDAQ:RGEN – Get Rating) – Jefferies Financial Group decreased their Q1 2023 EPS estimates for Repligen in a report issued on Wednesday, November 2nd. Jefferies Financial Group analyst B. Couillard now anticipates that the biotechnology company will post earnings per share of $0.70 for the quarter, down from their prior forecast of $0.89. […]

US Bancorp DE boosted its position in Repligen Co. (NASDAQ:RGEN – Get Rating) by 28.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,890 shares of the biotechnology company’s stock after purchasing an additional 5,085 shares during the quarter. US Bancorp DE’s holdings […]

Repligen Co. (NASDAQ:RGEN – Get Rating) – Equities research analysts at SVB Leerink dropped their Q1 2023 earnings per share estimates for Repligen in a research report issued on Wednesday, October 19th. SVB Leerink analyst P. Souda now anticipates that the biotechnology company will post earnings of $0.81 per share for the quarter, down from […]